Bristol-Myers Squibb has teamed up with Nvidia to build a dedicated AI supercomputer designed to transform how the pharmaceutical giant discovers and develops drugs. The facility, powered by Nvidia’s DGX SuperPOD technology, has been operational since March 2024 and represents one of the most ambitious AI infrastructure plays in the pharma industry to date.
What BMS actually built
The partnership centers on what both companies call an “AI Center of Excellence,” essentially an AI factory purpose-built for pharmaceutical research. The infrastructure runs on Nvidia’s DGX SuperPOD platform, with Equinix providing colocation services and Mark III Systems handling implementation.
The system is training foundational AI models on hundreds of thousands of CT and MR scans from clinical trials, using Nvidia’s MONAI framework and self-supervised learning techniques to build oncology-specific models. Beyond medical imaging, the AI factory handles training large language models and running deep clinical data analyses. The primary target is predicting patient outcomes in immuno-oncology.
BMS reported a 55% reduction in overall computing costs compared to its previous setup. The move represents a deliberate strategic pivot away from traditional cloud solutions and single-node computing setups toward dedicated high-performance computing infrastructure.
